Abstract:Aim: To study the hypoglycemic effect of rhFGF21 in vitro and in vivo by using liver cells, muscle cells, preadipocytes and ob/ob mice. Methods: GOD-POD kits were used for determination of cellular glucose uptake in normal human liver cell line (HL7702) , rat muscle cell line(L-6) , and mouse preadipocytes (3T3-L1) ; rhFGF-21 was subcutaneously and continuously injected, at the dose of 0.6 μg·g -1 per day, for 7 days, and the levels of fasting blood glucose on day 0, 3 and 7 after administration were recorded and compared to those of the saline-treated control; rhFGF-21 was subcutaneously and continuously injected, at the dose of 0.6 μg·g -1 per day, for 9 days. Oral glucose tolerance test was done 1 h after the last administration. Briefly, glucose solution was administered intragastrically at the dose of 2 mg·g -1, and the concentration of blood glucose was detected 30 min, 60 min, 120 min after glucose administration; rhFGF-21 was subcutaneously and continuously injected, at the dose of 2.5 μg¶g -1 per day, for 7 days, and postprandial blood glucose concentrations were detected on day 0,3, and 7 after the administration. Results: rhFGF21 at the concentration of 3. 9 mg·L -1 ∼ 100 mg ·L -1 significantly promoted glucose absorption in HL7702 cells in a dose-dependent manner (P < 0.01) ; rhFGF21 at the dose of 0.3 mg·L -1 ∼ 250 mg·L -1 significantly increased glucose consumption in L6 muscle cells(P <0.05) ; rhFGF21 at the dose of 12.6 mg ·L -1 ∼100 mg·L -1 significantly promoted the glucose absorption in differentiated 3T3-L1 cells in a dose-dependent manner (P < 0.05) ; in vivo blood glucose experiment showed that rhFGF-21 treatment greatly reduced blood glucose concentration and improved glucose tolerance in ob/ob mice. Conclusions: rhFGF21 treatment increases glucose absorption in liver cells, muscle cells and adipose cells; rhFGF-21 treatment also reduces fasting and postprandial blood glucose concentration in ob/ob mice, exhibiting its function of improving the amount of glucose tolerance.

Large-Scale Expression, Purification, and Glucose Uptake Activity of Recombinant Human Fgf21 in Escherichia Coli

[Cloning, Expression and Glucose Regulation Activity of Human FGF-21].

Expression of Recombinant H-Fgf21 in Periplasmic Space of Escherichia Coli

Cloning, expression and glucose regulation activity of human FGF-21 HOU Yu-Ting, LI Jin-Nan, REN Gui-Ping, LIU Ming-Yao, SUN Guo-Peng, WANG Wen-Fei, LI De-Shan

[Efficient Expression of Soluble Human FGF-21 and Its Glucose Regulation Activity].

[Improvement of Yield and Purity of Human Fibroblast Growth Factor-21].

Soluble Expression and Preparation of Recombinant Human Fibroblast Growth Factor 21 in E.coli

[Expression and Pharmacological Evaluation of Fusion Protein FGF21-L-Fc].

Optimization and Characterization of a Novel FGF21 Mutant

Human Fibroblast Growth Factor-21 Regulates Glucose Uptake in 3T3-L1 Adipocytes

Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein

Pilot-scale Production and Characterization of PEGylated Human FGF-21 Analog.

Enhancement of FGF21 Expression by Site-Directed Mutagenesis

Establishment of a Novel Method for Rapid Screening of Eukaryotic Cell Lines Stably Expressing High Level FGF-21

Stability and Glucose Regulation of FGF21 after Modified with Arginines*

A Better Anti-Diabetic Recombinant Human Fibroblast Growth Factor 21 (Rhfgf21) Modified With Polyethylene Glycol

High-Level Soluble Expression of Higf-1 Fusion Protein in Recombinant Escherichia Coli

Dynamic FGF21 Expression under Exercise , Fasting and Food Components

Utilization of SUMO Expression Vector to Efficiently Express Mouse FGF-21 and Studying of Its Bioactivity

The studies on hypoglycemic effect of rhFGF21 both in vitro and in vivo

FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance.